MARKET

CYTR

CYTR

Cytrx
OTCMQB
0.092
0.000
0.00%
Closed 16:00 09/28 EDT
OPEN
--
PREV CLOSE
0.092
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
4.700
52 WEEK LOW
0.052
MARKET CAP
4.14M
P/E (TTM)
-0.2705
1D
5D
1M
3M
1Y
5Y
CytRx Corporation Relaunches as LadRx Corporation
LOS ANGELES, September 23, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation.
Business Wire · 5d ago
European patent office awards CytRx patent for LADR platform
CytRx Corporation (OTCQB:CYTR) <a href="https://seekingalpha.com/pr/18929754-european-patent-office-awards-cytrx...
Seekingalpha · 09/07 14:26
European Patent Office Awards CytRx Key Patent
LOS ANGELES, September 07, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has been awarded a key patent by the Europ...
Business Wire · 09/07 13:00
CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors
LOS ANGELES, August 09, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (...
Business Wire · 08/09 12:00
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
LOS ANGELES, May 17, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by Ke...
Business Wire · 05/17 12:00
CytRx Partners with Oncology Development Expert to Advance LADR Platform
LOS ANGELES, April 20, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has partnered with oncology development expert...
Business Wire · 04/20 12:00
CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress
LOS ANGELES, March 21, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to stockholders.
Business Wire · 03/21 12:00
Orphazyme Calls For Court-Mediated Restructuring, Lays Off 50% Workforce
Benzinga · 03/11 15:42
More
About CYTR
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

Webull offers kinds of CytRx Corporation stock information, including OTCMQB:CYTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYTR stock methods without spending real money on the virtual paper trading platform.